GH Research PLC
No enriched coverage for $GHRS in the last 7 days.
No SEC Form 4 filings for $GHRS in the last 30 days.
See all $GHRS insider activity →Simply Wall St reports GH Research PLC (GHRS) posted net losses of $15.15M for Q2 2026 and $34.11M for the six months ended June 30, 2026, with basic loss per share of $0.23 and $0.53 from continuing operations. The article links the wider losses to higher spending, cash burn, and milestone progress for its GH001 program.
RA Capital Management, L.P. and affiliated funds, including Peter Kolchinsky and Rajeev Shah, filed a Schedule 13G/A stating they beneficially own 4,897,182 ordinary shares of GH Research PLC (GHRS), or 7.1% of the class. The filing cites 68,642,287 shares outstanding as of an issuer Form 6-K filed Aug. 6, 2026.
Lynx1 Capital Management LP and Weston Nichols reported beneficial ownership of GH Research PLC ordinary shares. Using 68,608,919 shares outstanding as of May 12, 2026, they collectively hold 13,263,288 shares, or 19.3% of the class, with shared voting and dispositive power, and rights to dividends and sale proceeds.
Recent GHRS coverage spans financial news, market movers and earnings.
The update reinforces a higher cash-burn and dilution-risk narrative, with near-term catalysts still tied to clinical/regulatory progress rather than financial improvement.
The filing signals a new, sizable institutional stake that can affect perceived control dynamics and future activism risk, but it is not an operational catalyst by itself.
A large, near-blockholder stake can shift governance expectations and increase takeover or strategic-interest speculation, but the filing itself is not an operational catalyst.
The article frames a valuation premium (P/B 5.6x) versus losses and no-revenue outlook, implying sentiment-driven risk if execution or funding weakens.
The article is a cash-burn narrative shift tied to reported losses and a referenced $200M ATM facility filing, implying higher funding sensitivity for GHRS.
alphai scores every news story that mentions GHRS with an AI model for sentiment and relevance, and aggregates insider trades from GH Research PLC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Simply Wall St reports GH Research PLC (GHRS) posted net losses of $15.15M for Q2 2026 and $34.11M for the six months ended June 30, 2026, with basic loss per share of $0.23 and $0.53 from continuing operations. The article links the wider losses to higher spending, cash burn, and milestone progress for its GH001 program.
6 min readRA Capital Management, L.P. and affiliated funds, including Peter Kolchinsky and Rajeev Shah, filed a Schedule 13G/A stating they beneficially own 4,897,182 ordinary shares of GH Research PLC (GHRS), or 7.1% of the class. The filing cites 68,642,287 shares outstanding as of an issuer Form 6-K filed Aug. 6, 2026.
2 min readLynx1 Capital Management LP and Weston Nichols reported beneficial ownership of GH Research PLC ordinary shares. Using 68,608,919 shares outstanding as of May 12, 2026, they collectively hold 13,263,288 shares, or 19.3% of the class, with shared voting and dispositive power, and rights to dividends and sale proceeds.
2 min readSimply Wall St reports GH Research (Nasdaq: GHRS) posted Q2 2026 results with a net loss of $15.15 million and basic loss per share of $0.23 from continuing operations. Despite wider losses, the stock rose sharply in 2026, with YTD return of 123.04% and 1-year total shareholder return of 150.25%. The article notes a 5.6x price-to-book versus 2.6x US pharma and 5.2x peers.
6 min readGH Research PLC reported Q2 2026 net loss of US$15.15 million, up from US$9.29 million a year earlier, with basic and diluted loss per share from continuing operations rising to US$0.23 from US$0.15. First-half 2026 net loss increased to US$34.11 million from US$20.10 million, raising near-term funding and dilution concerns.
6 min readGH Research PLC (GHRS) shares hit an all-time high of $31.41, up 146.9% over the past year, with market cap around $2.1B, according to Investing.com/InvestingPro. The article also cites Phase 2a results for inhaled mebufotenin (GH001) in postpartum depression, and Q1 2026 updates. Cantor Fitzgerald raised its price target to $35; others adjusted targets to $65 and $39.
3 min readGH Research (GHRS) rose about 12% premarket after reports that Eli Lilly (LLY) is in discussions to acquire Atai Life Sciences (ATAI). Atai shares reportedly jumped up to 53%. RBC said GH Research could benefit because its late-stage candidate GH001 is similar to Atai’s BPL-003. No deal was confirmed.
6 min readBloomberg reported a deal involving AtaiBeckley, highlighting its mebufotenin program. GH Research’s lead asset GH001, delivered via proprietary inhalation, is compared with AtaiBeckley’s BPL-003. GH001 Phase 2b TRD results were published in JAMA Psychiatry, with Day 8 remission 53.9%-63.6%. GH Research shares rose 11.40% to $29.99.
4 min readUS stock index futures fell after renewed selloff in Korea following the Bank of Korea’s first rate hire in three years. S&P 500 futures were down 0.3% and Nasdaq 100 down 0.8% at 8:15am ET. TSMC raised sales and spending outlook, including an extra $100B US capex plan, but AI and semis still weakened. Corporate movers included ATAI +34% on an Eli Lilly acquisition report, GE -4%, UAL -3%, and UNH +7%.
7 min readU.S. index futures were mixed as investors weighed Middle East tensions and easing inflation signals. Taiwan Semiconductor Manufacturing reported Q2 profit up 77% to a record, EPS $4.31 vs $3.80 estimates, but shares fell ~4% on higher capex and margin concerns. UnitedHealth rose 7.6% on Q2 adjusted EPS $6.38 beating forecasts. Abbott gained 4.4%.
4 min read
